Zambon is a leading pharmaceutical and chemical multinational. Founded in 1906 in Italy, Zambon operates directly on three continents – Europe, North & South America and Asia. It has 2500 employees spread in 14 countries and consolidated sales of €483m.
Zambon Company S.p.A. is the holding company of the Zambon Group, consisting of fine chemicals company ZaCh System, pharmaceuticals multinational Zambon S.p.A. and corporate venture specialist Z-Cube the corporate venture arm of the group which has launched three start-up companies — PharmEste s.r.l., SuppreMol GmbH and ProtAffin Biotechnologie AG.
Z-Cube is a corporate company of Zambon Company S.p.A. focused on DDT exploitation. They convert promising technologies from university laboratories or early start-ups into a number of commercial opportunities, to generate revenue growth for all parties involved.
ZaCh System’s expertise and proprietary patents in process chemistry are wide-ranging, extending from asymmetric transformation and resolution to solid state analysis and control, the multistep synthesis of complex APIs and separation and purification.
In recent years, Zambon has entered a new growth phase with a renewed path to provide innovative solutions to improve patients’ quality of life, with a specialization in treating severe diseases such as Parkinson’s and Cystic Fibrosis.
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
